Axon Enterprise, Inc. Interest Paid increased by 10768.3% to $54.12M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10768.3%, from $498.00K to $54.12M. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $877.00K | $877.00K | $877.00K | $877.00K | $0.00 | $498.00K | $54.12M |
| QoQ Change | — | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | >999% |
| YoY Change | — | — | — | — | — | — | — | — | -100.0% | — | >999% |